ChemoCentryx Information
Summary
ChemoCentryx is a public company that has been in the industry for 28 years. The company currently specializes in the Biotechnology, Pharmaceuticals areas. The position of the Chairman & CEO is occupied by Thomas J. Schall. Its headquarters is located at San Carlos, California, USA. The number of employees ranges from 100 to 250. The annual revenue of ChemoCentryx varies between 25M and 100M. Total funding of the company - $679.3M. To connect with ChemoCentryx employee register on SignalHire.
Industries
Biotechnology
Headquarters Location
Employees Size
100-200 employees
Specialties
Biopharmaceutical, autoimmune diseases, inflammatory disorders, orphan and rare diseases, ANCA-associated vasculitis, oral therapeutics, immuno-oncology, Hidradenitis Suppurativa, Chronic Kidney Disease, Diabetic Nephropathy, Pancreatic Cancer, C3 Glomerulopathy, Small Molecule Therapeutics, Chemoattractant System, Chemokine, Drug Discovery, Inflammatory Bowel Disease (IBD), Rheumatoid Arthritis (RA), Avacopan, Complement Receptor, ADVOCATE, AURORA, LUMINA, TAVNEOS
SIC Code
2834
DMA Code
San Francisco Bay Area
Founded
1997
Estimated Annual Revenue
$25M - 100M
Operating Status
Independent Company
Competitors
Founded | Type | Employees | Revenue | Funding | |
|---|---|---|---|---|---|
| 1979 | Public Company | 250 - 500 | 6.5M | $296.4M | |
| 2013 | Public Company | 100 - 250 | 89.2M | $204.8M | |
| 2000 | Public Company | 25 - 100 | 25.9M | $322.5M | |
| 2014 | Public Company | 25 - 100 | < 1M | $55M | |
| 2008 | Privately Held | 25 - 100 | 2.2M | $160.5M | |
| 2009 | Public Company | 1.0K - 5.0K | 45M | $634.9M | |
| 2013 | Public Company | 1.0K - 5.0K | 106M | $1.5B | |
| 1993 | Public Company | 1.0K - 5.0K | 50.2M | $526.4M | |
| 1992 | Privately Held | 25 - 100 | 14.1M | $68.6M | |
| 1994 | Public Company | 200-500 | - | $- | |
| 2008 | - | 500-1000 | - | $- | |
| - | - | 10-50 | - | $- |
Employees Turnover 3 quarter 2025
Length of Employment
